Jan 30, 2020 - Health

Zolgensma's lucrative Q4

Novartis said yesterday that Zolgensma — the gene therapy that's the most expensive drug in the world — brought in $186 million in the fourth quarter of 2019, STAT reports.

Why it matters: It suggests that the drug's enormous price tag isn't blocking patients from accessing it, although the costs are ultimately borne through premiums and by taxpayers.

By the numbers: About 200 patients have been treated with Zolgensma since it launched in June, Novartis said.

  • The company said it has reimbursement agreements that cover 97% of commercially-insured patients and 50% of Medicaid patients.

Go deeper: A new multimillion dollar drug

Go deeper